Frequency Therapeutics Provides Statement of Support for the Hearing Loss Association of America’s Externally-Led Patient-F...
May 20 2021 - 8:30AM
Business Wire
Frequency Therapeutics, Inc., (Nasdaq: FREQ) today shared a
statement from David L. Lucchino, Frequency’s Chief Executive
Officer, in support of the Hearing Loss Association of America
(HLAA) and its efforts to advance the voice of the patient in
leading the first-ever Externally-Led Patient-Focused Drug
Development (EL-PFDD) meeting on sensorineural hearing loss
(SNHL).
Patient-Focused Drug Development meetings are designed to
provide the U.S. Food and Drug Administration (FDA) an opportunity
to hear directly from patients, their families, caregivers and
advocates on the impact of disease on daily life and their
experiences with currently available interventions. This input
helps inform the FDA’s decisions and oversight both during drug
development and review of marketing applications for new drugs.
This is the first program focused specifically on SNHL, the most
common form of hearing loss.
SNHL typically results from damage to the inner ear, also called
the cochlea. This damage may occur due to chronic noise exposure,
aging, certain viral infections or exposure to drugs that are toxic
to the ear. This type of damage impacts hundreds of millions of
individuals worldwide.
“HLAA has been empowering patients with hearing loss for decades
and continues to be at the forefront of championing the needs of
individuals impacted by hearing loss. Their efforts are essential
to elevating the voice of patients and caregivers by building
awareness of the need for greater access to treatment and to
advance new areas of innovation. As ongoing research and
development progresses for a wide range of therapeutics and
modalities to potentially repair or restore hearing, understanding
the benefits and gaps in the current standard of care will be
crucial in helping inform future discussions on the role of new
treatment options for patients and providers. HLAA’s impact is
evident by the breadth of organizations they have convened for this
meeting, spotlighting the extent of the need for new advances in
the field of hearing and the impact of hearing health on overall
health. Their work to drive this EL-PFDD meeting will provide a
crucial window into the lives of individuals who struggle with
sensorineural hearing loss, the impact of the condition on their
quality of life and the need to bring new solutions to patients in
this underserved area of medicine.”
The Externally-Led Patient Focused Drug Development meeting on
SNHL will be held on Tuesday, May 25, from 10 a.m. to 3 p.m. ET.
Interested parties may register for the virtual interactive meeting
through HLAA’s website, www.hearingloss.org.
About Frequency Therapeutics
Frequency Therapeutics is a leader in the development of
medicines designed to activate progenitor cells within the body to
treat degenerative diseases. The Company’s progenitor cell
activation (PCA) approach stimulates progenitor cells to create
functional tissue with the aim of developing disease modifying
therapies. The Company’s lead product candidate, FX-322, is
designed to regenerate auditory hair cells to restore hearing
function. FX-322 is being evaluated in multiple ongoing clinical
studies in patients with sensorineural hearing loss. The Company
also is evaluating additional diseases where its PCA approach could
create functional tissue, including in a pre-clinical program in
multiple sclerosis.
Headquartered in Lexington, Mass., Frequency has an ex-U.S.
license and collaboration agreement with Astellas Pharma Inc. for
FX-322, as well as additional collaboration and licensing
agreements with academic and nonprofit research organizations
including Massachusetts Eye and Ear, Mass General Brigham,
Massachusetts Institute of Technology, The Scripps Research
Institute and Cambridge Enterprises Limited. For more information,
visit www.frequencytx.com and follow Frequency on Twitter
@Frequencytx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210520005166/en/
Investor Contact: Carlo Tanzi, Ph.D. Kendall Investor Relations
ctanzi@kendallir.com 617-914-0008
Media Contact: Suzanne Day Frequency Therapeutics
sday@frequencytx.com 781-496-2211
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From Apr 2023 to Apr 2024